Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214753) titled 'A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab sc Injection in Italy' on Oct. 6.

Study Type: Observational

Primary Sponsor: AstraZeneca

Condition: Severe Eosinophilic Asthma

Intervention: Biological: benralizumab

Recruitment Status: Not recruiting

Date of First Enrollment: December 19, 2025

Target Sample Size: 335

Countries of Recruitment: Italy

To know more, visit https://clinicaltrials.gov/study/NCT07214753

Published by HT Digital Content Services with permission from Health Daily Digest....